We are live on ! Find out more
KURA icon

Kura Oncology

182 hedge funds and large institutions have $474M invested in Kura Oncology in 2025 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 84 increasing their positions, 44 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

91% more repeat investments, than reductions

Existing positions increased: 84 | Existing positions reduced: 44

66% more call options, than puts

Call options by funds: $434K | Put options by funds: $261K

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

0% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 29

1% less funds holding

Funds holding: 183182 (-1)

4.79% less ownership

Funds ownership: 99.59%94.8% (-4.8%)

11% less capital invested

Capital invested by funds: $531M → $474M (-$57.3M)

Holders
182
Holders Change
-1
Holders Change %
-0.55%
% of All Funds
2.4%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
29
Increased
84
Reduced
44
Closed
29
Calls
$434K
Puts
$261K
Net Calls
+$173K
Net Calls Change
+$217K

KURA Hedge Fund Activity: Q2 2025 in Review

182 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Kura Oncology (KURA) for Q2 2025, worth a combined $474M — down 11% from $531M a quarter earlier.

Fund positioning in KURA was balanced in Q2 2025: 29 funds opened new positions, 29 closed out, 84 added to existing stakes and 44 trimmed.

The largest buyer was EcoR1 Capital, adding an estimated $9.56M. The largest seller was RA Capital Management, exiting entirely with an estimated $26.4M sold.

  • 182 institutional investors held Kura Oncology (KURA) as of Q2 2025, down from 183 in Q1 2025.
  • Funds reported $474M of Kura Oncology stock for Q2 2025, down 11% quarter-over-quarter.
  • 29 funds opened new Kura Oncology positions in Q2 2025 and 29 closed out, a net change of 0 holders.
  • The largest Kura Oncology buyer in Q2 2025 was EcoR1 Capital, an estimated $9.56M added.
  • The largest Kura Oncology seller in Q2 2025 was RA Capital Management, an estimated $26.4M sold.

Based on aggregated 13F filings for Q2 2025.